Patents Assigned to Oncotherapy Science, Inc.
  • Publication number: 20110293645
    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 1, 2011
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Publication number: 20110294123
    Abstract: The present invention provides methods for detecting and/or diagnosing cancer through the determination of the expression level of the STC2 gene. The gene was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer. Moreover, the present invention provides double-stranded molecules targeting the STC2 gene, which are suggested to be useful in the treatment of cancer. The compositions and methods of the present invention find particular applicability to prostate cancer, more specifically, castration-resistant prostate cancer and aggressive prostate cancer.
    Type: Application
    Filed: November 18, 2009
    Publication date: December 1, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Takuya Tsunoda
  • Publication number: 20110280898
    Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from INHBB that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical compositions containing the INHBB polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients.
    Type: Application
    Filed: August 14, 2009
    Publication date: November 17, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
  • Patent number: 8053183
    Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. a detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. these genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. among the candidate molecular target genes, ECT2 and CDC45L and DKK1 are further characterized. treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: November 8, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Patent number: 8053556
    Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: November 8, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori
  • Publication number: 20110263012
    Abstract: The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.
    Type: Application
    Filed: April 5, 2011
    Publication date: October 27, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Publication number: 20110263679
    Abstract: Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.
    Type: Application
    Filed: August 21, 2009
    Publication date: October 27, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Akira Togashi
  • Publication number: 20110262471
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 27, 2011
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Publication number: 20110262463
    Abstract: The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.
    Type: Application
    Filed: August 24, 2009
    Publication date: October 27, 2011
    Applicant: Oncotherapy Science ,Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Akira Togashi
  • Patent number: 8044193
    Abstract: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS and IDC cells. The present invention further provides means for predicting and preventing breast cancer metastasis using BRC-associated genes having unique altered expression patterns in breast cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and method for vaccinating a subject against breast cancer.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: October 25, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru
  • Publication number: 20110250219
    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Application
    Filed: March 3, 2011
    Publication date: October 13, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
  • Publication number: 20110251090
    Abstract: The present invention relates to the roles played by TTLL4 genes in pancreatic cancer carcinogenesis and features a method for treating or preventing pancreatic cancer by administering a double-stranded molecule against one or more of the TTLL4 genes or a composition, vector or cell containing such a double stranded molecule. Also, disclosed are methods of identifying compounds for treating and preventing pancreatic cancer, using as an index their effect on the over-expression of TTLL4 in the pancreatic cancer cell.
    Type: Application
    Filed: August 21, 2009
    Publication date: October 13, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Akira Togashi
  • Patent number: 8034578
    Abstract: The present invention provides the method of predicting an non-small cell lung cancer (NSCLC) prognosis.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: October 11, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Patent number: 8029981
    Abstract: The present invention provides a method for inhibiting growth of a cancer cell, particularly a renal cell carcinoma, by contacting the cell with a composition composed of an HIG2 siRNA or HIG2 antibody. Methods of diagnosing renal cell cancer are also provided within the present invention.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: October 4, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri
  • Publication number: 20110237518
    Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.
    Type: Application
    Filed: August 21, 2009
    Publication date: September 29, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Akira Togashi
  • Publication number: 20110223687
    Abstract: Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
    Type: Application
    Filed: May 23, 2011
    Publication date: September 15, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Publication number: 20110212115
    Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
    Type: Application
    Filed: July 30, 2009
    Publication date: September 1, 2011
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa
  • Patent number: 8003098
    Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: August 23, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima, Yoshiro Kishi, Motoki Kuhara, Shiyo Nishida, Midori Shinohara
  • Publication number: 20110200626
    Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.
    Type: Application
    Filed: June 10, 2009
    Publication date: August 18, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 7998695
    Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: August 16, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru